Product Description
Chimeric antigen receptor (CAR) T cell therapies are demonstrating success in the treatment of B cell cancers. However, the adaptation of this platform to other liquid and solid tumors has proven more challenging. Expression Therapeutics has developed novel gene therapy strategies to overcome these challenges utilizing mRNA technology to engineer γδ T cells with novel CAR-designs. The initial indications include B/T-cell leukemia/lymphoma and acute myeloid leukemia (AML). (Sourced from: https://www.expressiontherapeutics.com/therapeutics)
Mechanisms of Action: CAR-T
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Expression Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: T-Cell Leukemia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|